Eli Lilly plans to acquire Dice Therapeutics — a biopharmaceutical company that develops oral therapeutics for autoimmune diseases — in a deal valued at $2.4 billion.
Read the full post on Becker's Hospital Review - Healthcare News
Eli Lilly to acquire Dice Therapeutics for $2.4B
